EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment

Anna Eligulashvili, Moshe Gordon iD, Jimmy S Lee, Jeylin Lee, Shiv Mehrotra-Varma, Jai Mehrotra-Varma, Kevin Hsu, Imanyah Hilliard, Kristen Lee, Arleen Li iD, Muhammed Amir Essibayi iD, Judy Yee iD und 4 weitere

PLOS Medicine · 04.04.2024 · 21 (4) · e1004263

DOI: 10.1371/journal.pmed.1004263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 04.04.2024. Verfasst von Anna Eligulashvili und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America. Hauptthemen laut MEDLINE: COVID-19, Stroke. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute neurological manifestation is a common complication of acute Coronavirus Disease 2019 (COVID-19) disease. This retrospective cohort study investigated the 3-year outcomes of patients with and without significant neurological manifestations during initial COVID-19 hospitalization. Methods and findings Patients hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection between 03/01/2020 and 4/16/2020 in the Montefiore Health System in the Bronx, an epicenter of the early pandemic, were included. Follow-up data was captured up to 01/23/2023 (3 years post-COVID-19). This cohort consisted of 414 patients with COVID-19 with significant neurological manifestations and 1,199 propensity-matched patients (for age and COVID-19 severity score) with COVID-19 without neurological manifestations. Neurological involvement during the acute phase included acute stroke, new or recrudescent seizures, anatomic brain lesions, presence of altered mentation with evidence for impaired cognition or arousal, and neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnormalities, ataxia, dysautonomia, and skeletal muscle injury with normal orientation and arousal signs). There were no significant group differences in female sex composition (44.93% versus 48.21%, p = 0.249), ICU and IMV status, white, not Hispanic (6.52% versus 7.84%, p = 0.380), and Hispanic (33.57% versus 38.20%, p = 0.093), except black non-Hispanic (42.51% versus 36.03%, p = 0.019). Primary outcomes were mortality, stroke, heart attack, major adverse cardiovascular events (MACE), reinfection, and hospital readmission post-discharge. Secondary outcomes were neuroimaging findings (hemorrhage, active and prior stroke, mass effect, microhemorrhages, white matter changes, microvascular disease (MVD), and volume loss). More patients in the neurological cohort were discharged to acute rehabilitation (10.39% versus 3.34%, p < 0.001) or skilled nursing facilities (35.75% versus 25.35%, p < 0.001) and fewer to home (50.24% versus 66.64%, p < 0.001) than matched controls. Incidence of readmission for any reason (65.70% versus 60.72%, p = 0.036), stroke (6.28% versus 2.34%, p < 0.001), and MACE (20.53% versus 16.51%, p = 0.032) was higher in the neurological cohort post-discharge. Per Kaplan–Meier univariate survival curve analysis, such patients in the neurological cohort were more likely to die post-discharge compared to controls (hazard ratio: 2.346, (95% confidence interval (CI) [1.586, 3.470]; p < 0.001)). Across both cohorts, the major causes of death post-discharge were heart disease (13.79% neurological, 15.38% control), sepsis (8.63%, 17.58%), influenza and pneumonia (13.79%, 9.89%), COVID-19 (10.34%, 7.69%), and acute respiratory distress syndrome (ARDS) (10.34%, 6.59%). Factors associated with mortality after leaving the hospital involved the neurological cohort (odds ratio (OR): 1.802 (95% CI [1.237, 2.608]; p = 0.002)), discharge disposition (OR: 1.508 (95% CI [1.276, 1.775]; p < 0.001)), congestive heart failure (OR: 2.281 (95% CI [1.429, 3.593]; p < 0.001)), higher COVID-19 severity score (OR: 1.177 (95% CI [1.062, 1.304]; p = 0.002)), and older age (OR: 1.027 (95% CI [1.010, 1.044]; p = 0.002)). There were no group differences in radiological findings, except that the neurological cohort showed significantly more age-adjusted brain volume loss ( p = 0.045) than controls. The study’s patient cohort was limited to patients infected with COVID-19 during the first wave of the pandemic, when hospitals were overburdened, vaccines were not yet available, and treatments were limited. Patient profiles might differ when interrogating subsequent waves.

Conclusions

Patients with COVID-19 with neurological manifestations had worse long-term outcomes compared to matched controls. These findings raise awareness and the need for closer monitoring and timely interventions for patients with COVID-19 with neurological manifestations, as their disease course involving initial neurological manifestations is associated with enhanced morbidity and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19StrokeHumansFemaleSARS-CoV-2Retrospective StudiesFollow-Up StudiesAftercarePatient DischargeSeizures

Autor:innen und Institutionen

  • Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America.
  • Department of Radiology, New York University Grossman School of Medicine, New York, New York, United States of America.
  • Department of Neurological Surgery, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America.
  • Department of Neurology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America.

ORCID-Profile: Moshe Gordon, Arleen Li, Muhammed Amir Essibayi, Judy Yee, David J Altschul, Mark F Mehler, Tim Q Duong

Zitieren

APA

Eligulashvili, A., Gordon, M., Lee, J. S., Lee, J., Mehrotra-Varma, S., Mehrotra-Varma, J., Hsu, K., Hilliard, I., Lee, K., Li, A., Essibayi, M. A., Yee, J., Altschul, D. J., Eskandar, E., Mehler, M. F., & Duong, T. Q. (2024). Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment. PLOS Medicine, 21(4), e1004263. https://doi.org/10.1371/journal.pmed.1004263

Vancouver

Eligulashvili A, Gordon M, Lee JS, Lee J, Mehrotra-Varma S, Mehrotra-Varma J, et al. Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment. PLOS Medicine. 2024;21(4):e1004263. doi:10.1371/journal.pmed.1004263

BibTeX
@article{Eligulashvili2024,
  author = {Eligulashvili, Anna and Gordon, Moshe and Lee, Jimmy S and Lee, Jeylin and Mehrotra-Varma, Shiv and Mehrotra-Varma, Jai and Hsu, Kevin and Hilliard, Imanyah and Lee, Kristen and Li, Arleen and Essibayi, Muhammed Amir and Yee, Judy and Altschul, David J and Eskandar, Emad and Mehler, Mark F and Duong, Tim Q},
  title = {Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment},
  journal = {PLOS Medicine},
  year = {2024},
  volume = {21},
  number = {4},
  pages = {e1004263},
  doi = {10.1371/journal.pmed.1004263}
}
Kostenlos starten →